


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled):
2. (Cancelled):
3. (Cancelled):
4. (Previously Presented): A compound of Formula I:



wherein

R^1 is alkyl having 1 to 8 carbon atoms wherein optionally one or more $-\text{CH}_2\text{CH}_2-$ groups are replaced in each case by $-\text{CH}=\text{CH}-$ or $-\text{C}\equiv\text{C}-$ groups,

alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more $-\text{CH}_2\text{CH}_2-$ groups are replaced in each case by $-\text{CH}=\text{CH}-$ or $-\text{C}\equiv\text{C}-$ groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof,

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof,

aryl having 6 to 14 carbon atoms which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof ,

arylalkenyl having 8 to 16 carbon atoms, wherein the alkenyl portion has up to 5 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof;

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof, or

cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

R² is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen;

R³ is phenpropyl, -C(O)R⁴, -(CH₂)_nC(O)R⁴, -(CH₂)_nOR⁵, -(CH₂)_nSR⁵, -(CH₂)_nSO₂R⁴, -(CH₂)_nNR⁵R⁶, -CH₂CO₂R⁵, -CH₂CONR⁶R⁵, -(CH₂)_nNR⁶SO₂R⁴, -(CH₂)_nNR⁶COR⁴, or -CH₂CONHSO₂R⁴;

R⁴ is alkyl having 1 to 12 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,

cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonamido, arylsulphonamido, halogenated arylsulphonamido, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, aminosulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, aminosulphonyl, heterocycle, heterocyclic-alkyl, or combinations thereof, or

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof

and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; and

R⁵ is alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,

cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxy carbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonamido, arylsulphonamido, halogenated arylsulphonamido, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxy carbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, aminosulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which

is unsubstituted or substituted one or more times by halogen, aryl, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, aminosulphonyl, heterocycle, heterocyclic-alkyl, or combinations thereof, or

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof;

R⁶ is H,

alkyl having 1 to 12 carbon atoms wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH₂CH₂- groups are replaced in each case by -CH=CH- or -C≡C- groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,

cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF₃, OCF₃, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof;

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, alkoxycarbonyl, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof;

n is 0 or 1; and

pharmaceutically acceptable salts thereof;

wherein when R^3 is $-\text{CH}_2\text{CONR}^6\text{R}^5$, R^5 is benzyl, thiazolyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benzothiazolyl, tetrahydroisoquinoliny, thiadiazolyl, indolyl, indanyl, benzodioxanyl, $-\text{CH}_2$ -benzothiazolyl, or $-\text{CH}_2$ -pyridinyl, which in each case is substituted or unsubstituted.

5. (Cancelled):

6. (Cancelled):

7. (Cancelled):

8. (Previously Presented): A compound according to claim 4, wherein said compound is selected from:

(4S)-1-[N-(4,5-Dimethylthiazol)-2-yl]aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl]-2-pyrrolidone,
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl)-1-[N-(3-phenylpropyl)]-2-pyrrolidone,
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl)-1-[N-(2-phenoxylethyl)]-2-pyrrolidone,
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl)-1-[N-(2-phenylethyl)]-2-pyrrolidone,
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl)-1-(N-phenylsulfonylaminocarbonylmethyl)-2-pyrrolidone,
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl)-1-[N-(2-thiazolyl)aminocarbonylmethyl]-2-pyrrolidone,
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl)-1-[N-(2-phenylsulfonyl)ethyl]-2-pyrrolidone,
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)oxyphenyl)-1-[N-(2-

methylphenyl)sulfonylaminocarbonylmethyl]-2-pyrrolidone,
 (4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(2-(4-methoxyphenyl)oxyethyl)]-2-pyrrolidone,
 (4S)-1-[N-(2-(5-Chlorobenzoxazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,
 (4S)-1-[N-(2-(Benzothiazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,
 (4S)-1-[N-(2-(6-Fluorobenzothiazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,
 (4S)-1-[N-(2-(Benzimidazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone, and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

9. (Currently Amended): A compound according to claim 4, wherein said compound is selected from:

(4S)-1-[2-(3-Chlorophenoxy)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,
 (4S)-1-[2-(4-Isopropylphenoxy)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(4-methylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(5-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(6-methylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-1-[N-(4-methoxybenzothiazol-2-

yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(6-Ethoxycarbonylbenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(6-trifluoromethoxybenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(4-tert-Butylthiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-1-[2-(4-Isopropylphenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-1-[2-(3-Chlorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-1-[2-(2,3-Difluorophenoxy)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[2-(1,2,3,4-tetrahydroisoquinolin-2-yl)carbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[1-(1,2,3,4-tetrahydroquinolin-2-yl)carbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(6-Fluorobenzothiazol-2-yl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-1-[2-(Benzothiazol-2-yl)oxyethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-1-[2-(6-Fluorobenzothiazol-2-yl)thioethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(6-Fluorobenzothiazol-2-yl)aminoethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(Benzothiazol-2-yl)aminoethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-4-phenoxybenzamide,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(4-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(6-Chlorobenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-methyl-N-(thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(Benzothiazol-2-yl)-N-(cyclopropylmethyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(Indol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(Indan-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(5-Chlorothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(4-phenylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(6-methoxybenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]benzamide,

(4S)-2,3-Difluoro-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-benzamide,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-4-methoxybenzamide,

(4S)-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[2-(4-trifluoromethylphenoxy)ethyl]-2-pyrrolidone,

(4S)-1-[N-(5-Cyclopropyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(Benzothiazol-6-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-

tetrahydrofuranyloxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(4-Ethoxycarbonylthiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-Cyclopropylmethyl-N-(6-fluorobenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-
 methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-(2-oxo-2-phenylethyl)-2-pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-(2-oxo-2-(4-methoxyphenyl)ethyl)-2-
 pyrrolidone,
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(2,2,3,3-tetrafluorobenzo-1,4-
 dioxan-6-yl)aminocarbonylmethyl]-2-pyrrolidone,
 (4S)-1-[N-(1,4-Benzodioxan-6-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(4-(4-Fluorophenyl)thiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(4,6-Difluorobenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(4-Carboxythiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,
 (4S)-1-[2-(2-Fluorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-
 pyrrolidone,
 (4S)-1-[2-(3-Fluorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-
 pyrrolidone,
 (4S)-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[2-(4-methoxyphenylthio)ethyl]-2-
 pyrrolidone,
 (4S)-1-[N-(2,3-Difluorobenzyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,
 (4S)-1-[N-(5-Cyclopropylmethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-

(3R)-tetrahydrofuran-2-yl]-2-pyrrolidone,

(4S)-1-[N-(3-Fluorobenzyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(2-methylbenzyl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(4-Methanesulfonylbenzyl)aminocarbonylmethyl]-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-2-pyrrolidone,

(4S)-1-[N-(4-Aminosulfonylbenzyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]-2-pyrrolidone,

(4S)-1-[N-(Benzothiazol-2-yl)methylaminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(3-methylpyridin-2-yl)methylaminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(4-(3-pyridyl)thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(4-(2-pyridyl)thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(4-(4-pyridyl)thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]-1-[N-(5-methoxycarbonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(3,4-methylenedioxyphenyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(2-thienyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(2-thienylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(2-propyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(2-pyrazinyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-methoxymethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(2-tetrahydrofuran-2-yl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-aminosulfonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(4-methoxyphenyloxymethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(4-morpholinylcarbonylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(1-piperidinylcarbonylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(1-pyrrolidinylcarbonylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(4-piperidinyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(4-N-

tertbutyloxycarbonyl)piperidinyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone (4*S*)-1-[N-(2,3-Difluorophenylaminocarbonylmethyl)-4-(4-methoxy-3-(3*R*)-tetrahydrofuran-2-yl)-2-pyrrolidone, and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

10. (Currently Amended): A pharmaceutical composition comprising a compound of Claim 4 + and a pharmaceutically acceptable carrier.

11. (Original): A composition of claim 10, wherein the compound is provided in a unit dosage of 0.1 - 50 mg.

12. (Withdrawn; Currently Amended): A method for effecting PDE4 enzyme inhibition, enhancing cognition and/or treating psychosis in a patient comprising administering to said patient an effective amount of a compound according to Claim 4 +.

13. (Withdrawn): A method according to claim 12, wherein said compound is administered in an amount of 0.01-100 mg/kg of body weight/day.

14. (Withdrawn): A method according to claim 12, wherein said patient is a human.

15. (Withdrawn): A method of claim 12, wherein the patient is suffering from cognition impairment or decline.

16. (Withdrawn): A method according to claim 12, wherein said patient is suffering from memory impairment.

17. (Withdrawn): A method according to claim 16, wherein said patient is suffering from memory impairment due to Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, HIV, cardiovascular disease, head trauma or age-related cognitive decline.

18. (Withdrawn): A method according to claim 16, wherein said patient is suffering from memory impairment due to dementia.

19. (Withdrawn): A method according to claim 16, wherein said patient is suffering from memory impairment Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia, an acute neuronal disease, HIV or a cardiovascular disease.

20. (Withdrawn): A method according to claim 12, wherein said patient is suffering from a psychosis.

21. (Withdrawn; Currently Amended): A method according to ~~The method of~~ claim 20, wherein the psychosis is schizophrenia, bipolar or manic depression, major depression, drug addiction or morphine dependence.

22. (Withdrawn; Currently Amended): A method for treating a patient having a disease involving decreased cAMP levels comprising administering to said patient an effective amount of a compound according to Claim 4 ~~4~~.

23. (Withdrawn): A method of claim 12, wherein the patient is treated to effect PDE4 enzyme inhibition.

24. (Withdrawn; Currently Amended): A method of treating a patient suffering from an allergic or inflammatory disease comprising administering to said patient an effective amount of a compound according to Claim 4.

25. (Withdrawn): A method of claim 24, wherein the patient is suffering from chronic obstructive pulmonary disease.

26. (Withdrawn; Currently Amended): A method of treating a patient suffering from neurodegeneration resulting from a disease or injury comprising administering to said patient an effective amount of a compound according to Claim 4.

27. (Withdrawn; Currently Amended): A method according to ~~The method of~~ claim 26, wherein the disease or injury is stroke, spinal cord injury, neurogenesis, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), or multiple systems atrophy (MSA).

28. (Previously Presented): A compound according to claim 9, wherein said compound is 4-[4-Methoxy-3-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone or a physiologically acceptable salt thereof, wherein the compound can be in the form of a mixture of enantiomers, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

29. (Previously Presented): A compound according to claim 9, wherein said compound is (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-1-[N-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone or a physiologically acceptable salt thereof.

30. (Previously Presented): A compound according to claim 4, wherein R¹ is optionally substituted cyclopentyl, optionally substituted phenethyl, 3-tetrahydrofuryl, CHF₂, or cyclopropylmethyl.

31. (Previously Presented): A compound according to claim 4, wherein R^2 is CHF_2 and CH_3 .

32. (Previously Presented): A compound according to claim 4, wherein R^3 is -
 $(CH_2)_nOR^5$, $-(CH_2)_nSR^5$, $-(CH_2)_nSO_2R^4$, $-(CH_2)_nNR^5R^6$, $-CH_2CO_2R^5$, $-CH_2CH_2CO_2R^5$, $-CH_2CONR^6R^5$, $-(CH_2)_nNR^6SO_2R^4$, $-(CH_2)_nNR^6COR^4$, or $-CH_2CONHSO_2R^4$.

33. (Previously Presented): A compound according to claim 4, wherein R^3 is $CH_2CONR^6R^5$.

34. (Currently Amended): A compound according to claim 33, wherein R^5 is 2-thiazolyl which is unsubstituted or substituted by F, Cl, CF_3 , methoxymethyl, isopropyl, isobutyl ~~isopentyl~~, t-butyl, , carboxy, alkoxycarbonyl, cyclopropyl, cyclopropylmethyl, phenyl, pyridyl, piperidiny, 3,4-methylenedioxyphenyl, thienyl, pyrazinyl, tetrahydrofuranyl, morpholinyl, pyrrolidinyl, or thienylmethyl, or

1,3,4-thiadiazolyl which is unsubstituted or substituted by F, Cl, CF_3 , methyl, methoxymethyl, isopropyl, isobutyl ~~isopentyl~~, t-butyl, , carboxy, alkoxycarbonyl, cyclopropyl, cyclopropylmethyl, phenyl, pyridyl, piperidiny, 3,4-methylenedioxyphenyl, thienyl, pyrazinyl, tetrahydrofuranyl, morpholinyl, pyrrolidinyl, or thienylmethyl.

35. (Previously Presented): A compound according to claim 4, wherein R^1 is CHF_2 cycloalkyl, cycloalkylalkyl, heterocyclic group, or heterocyclicalkyl group; R^2 is CH_3 or CHF_2 ; R^3 is CH_2CONHR^5 ; and R^5 is substituted or unsubstituted 1,3,4-thiadiazolyl.

36. (Previously Presented): A compound according to claim 35, wherein R^1 is cyclopentyl, tetrahydrofuran, cyclopropylmethyl or CHF_2 .

37. (Previously Presented): A compound selected from:

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone-1-acetic acid,

(4S)-1-(N-(Methoxycarbonylmethyl)-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)-1-[N-(2-methylphenyl)-(N-methyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)-1-[N-(2-(6-methylpyridyl)-(N-methyl)aminocarbonylmethyl)-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl)-(N-methyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)-1-[N-(phenylaminocarbonylmethyl)-2-pyrrolidone;

(4S)-1-[N-(3-Chlorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)-1-[N-(3-methoxycarbonylphenyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl)-(N-ethyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl)-(N-isopropyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl)-(N-cyclopropylmethyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(4-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(4-Methoxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(2,6-Dimethylphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Isopropylphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl)-1-[N-(3,4-methylenedioxyphenyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl)-1-[N-(2-(4-trifluoromethyl)pyridyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(3-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone; and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

38. (Previously Presented): A compound according to claim 37, wherein said compound is selected from:

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl)-1-[N-(2-(6-methylpyridyl)-(N-methyl)aminocarbonylmethyl)]-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl)-(N-methyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone;

(4S)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl)-1-[N-(2-(4-trifluoromethyl)pyridyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(3-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl]-2-pyrrolidone; and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

39. (Previously Presented): A compound selected from:

(4S)-1-[N-(2,3-Difluorophenyl)-N-(2-methylpropyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Isopropoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(4-trifluoromethoxyphenyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(3-Fluorophenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-1-[N-(4-methoxyphenyl)-N-(methyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(4-Isopropylphenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3,4-Methylenedioxyphenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-tert-Butylphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(2,4-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3,5-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3,4-(Difluoromethylene)dioxyphenyl)-N-methylaminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3-Fluoro-4-methoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(2-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-

tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(3,4-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone,

(4S)-1-[N-(3,4-Difluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(4-Methanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(3-Fluoro-4-methylphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone,

(4R)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3S)-tetrahydrofuran-2-yl)-2-pyrrolidone,

(4S)-1-[N-(4-Carboxy-3-fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(4-Ethanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(4-Benzenesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(4-(4-Fluorobenzene)sulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-1-[N-(6-Ethylpyridin-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)-1-[N-(4-ethoxycarbonylphenyl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(4-tert-butyloxycarbonyl-3-fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl)-2-pyrrolidone and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

40. (Previously Presented): A compound according to claim 39, wherein said compound is selected from:

(4S)-1-[N-(2,3-Difluorophenyl)-N-(2-methylpropyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(3-Fluorophenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(2-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(3,4-Difluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(4-Methanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone,

(4S)-1-[N-(6-Ethylpyridin-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl]-2-pyrrolidone, and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

41. (Previously Presented): A pharmaceutical composition comprising a compound of Claim 37 and a pharmaceutically acceptable carrier.

42. (Previously Presented): A pharmaceutical composition comprising a compound of Claim 38 and a pharmaceutically acceptable carrier.

43. (Previously Presented): A pharmaceutical composition comprising a compound of Claim 39 and a pharmaceutically acceptable carrier.

44. (Previously Presented): A pharmaceutical composition comprising a compound of Claim 40 and a pharmaceutically acceptable carrier.

45. (Previously Presented): A compound according to claim 8, wherein said compound is selected from:

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl-1-(N-(phenylsulfonyl)aminocarbonylmethyl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl-1-[N-(2-thiazolyl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl-1-[N-(2-methylphenyl)sulfonylaminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(2-(6-Fluorobenzothiazol-2-yl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuran-2-yl)phenyl-2-pyrrolidone, and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

46. (Previously Presented): A compound according to claim 9, wherein said compound is selected from:

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl-1-[N-(4-methylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl-1-[N-(5-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(4-tert-Butylthiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl-2-pyrrolidone;

(4S)-1-[2-(4-Isopropylphenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]phenyl-2-pyrrolidone;

(4S)-1-[2-(3-Chlorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(6-Fluorobenzothiazol-2-yl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-2-pyrrolidone;

(4S)-1-[2-(Benzothiazol-2-yl)oxyethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(Benzothiazol-2-yl)aminoethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-4-phenoxybenzamide;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-1-[N-(4-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(5-Cyclopropyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-1-[N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-1-[N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranloxyphenyl]-1-[N-(5-methoxycarbonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone; and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.